What is the appropriate management and treatment for post‑streptococcal glomerulonephritis?

Management of Post-Streptococcal Glomerulonephritis

Post-streptococcal glomerulonephritis (PSGN) is a self-limiting disease that requires primarily supportive care—not immunosuppression—with treatment focused on managing hypertension, fluid overload, and electrolyte disturbances 1, 2.

Core Treatment Approach

The management of PSGN centers on supportive therapy because the disease resolves spontaneously in the vast majority of cases 1, 3, 4. Immunosuppressive agents are not indicated for typical PSGN and should be reserved only for rare presentations with crescentic or rapidly progressive glomerulonephritis 2.

Immediate Management Priorities

Fluid and Sodium Restriction:

• Restrict dietary sodium to <2.0 g/day (<90 mmol/day) to reduce edema and control blood pressure 5
• Implement fluid restriction in patients presenting with edema or hypertension 2

Diuretic Therapy:

• Diuretics are the preferred first-line agents for managing volume overload 6
• If response is insufficient, add mechanistically different diuretics 6
• In severe cases, high-dose furosemide (up to 4 mg/kg/day) may be necessary 7
• Monitor closely for hyponatremia, hypokalemia, GFR reduction, and volume depletion 6

Hypertension Management:

• Target systolic blood pressure <120 mm Hg using standardized office measurement in adults 6
• In children, target 24-hour mean arterial pressure at ≤50th percentile for age, sex, and height by ambulatory monitoring 6
• Use calcium channel blockers as first-line for stage 2 hypertension 2
• ACE inhibitors or ARBs can be used at maximally tolerated doses, but counsel patients to hold these medications during intercurrent illness or risk of volume depletion 6

Antibiotic Therapy

Eradicate streptococcal infection if still present, though antibiotics do not alter the course of established PSGN 1. However, in staphylococcus-associated GN, infective endocarditis-associated GN, and shunt nephritis, antibiotics are essential and required 2.

When to Escalate Care

Hospitalization is required for patients with 2:

• Significant edema
• Severe hypertension (stage 2)
• Acute kidney injury
• Life-threatening complications (pulmonary edema, hypertensive encephalopathy, critical hyperkalemia)

Critical complications requiring ICU-level care include 7:

• Acute pulmonary edema (may require mechanical ventilation)
• Critical hyperkalemia (>7.0 mmol/L)—manage with calcium, insulin-glucose, salbutamol, and aggressive diuresis
• Congestive heart failure
• Hypertensive encephalopathy

Kidney Biopsy Indications

Perform kidney biopsy in the following atypical scenarios 1, 2:

• Diagnostic uncertainty
• Rapidly progressive glomerulonephritis (RPGN)
• Nephrotic syndrome presentation
• Persistently low complement C3 beyond 12 weeks
• Atypical disease progression

Immunosuppression: The Exception, Not the Rule

Immunosuppressive therapy is suggested ONLY in patients with 2:

• Crescentic IRGN on biopsy
• Rapidly progressive glomerulonephritis with deteriorating kidney function

This represents a small minority of cases 1, 4. The general principle from KDIGO guidelines emphasizes choosing treatment regimens that avert immediate morbidity while minimizing harmful immunosuppression side effects 5, 6.

Monitoring and Follow-Up

All patients require long-term monitoring of 2:

• Serum creatinine
• Urinalysis (for persistent proteinuria and hematuria)
• Blood pressure

Poor prognostic indicators requiring closer surveillance include 4:

• Crescent formation on renal biopsy
• Renal insufficiency at presentation
• Persistent proteinuria or hypertension after acute episode
• Decreased complement levels with increased CRP and hypoalbuminemia

Common Pitfalls to Avoid

1. Do not routinely use immunosuppression—PSGN is self-limiting and immunosuppression exposes patients to unnecessary toxicity 1, 3

2. Do not forget to hold ACE inhibitors/ARBs during intercurrent illness—this prevents dangerous hypotension and acute kidney injury 6

3. Do not delay kidney biopsy in atypical presentations—particularly with low C3 persisting beyond 12 weeks or RPGN features 2

4. Do not overlook public health notification—suspected and confirmed cases must be reported immediately to regional public health authorities 8

Prognosis

Most patients make a full recovery from PSGN 1, 3, 4. However, a small percentage may develop persistent urinary abnormalities, hypertension, or progression to chronic kidney disease, necessitating long-term follow-up 4, 2.